HXN-1003

N/A

Report date: 2026/03/19 15:27:24
First In Class

Base Information

Drug NameHXN-1003
Drug Alias NameHXN-1003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor superfamily member 15 inhibitorsInterleukin-23 inhibitors
TargetsTumor necrosis factor superfamily member 15Interleukin-23
Therapy Area/IndicationsDermatitisInflammatory Bowel DiseasesColitis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaN/A
Originator CompaniesEarendil Labs
China Registration ClassN/A

Develop Information

Active CompaniesEarendil LabsSanofi
Inactive CompaniesN/A
Active IndicationsDermatitisInflammatory Bowel DiseasesColitis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A